These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31145232)

  • 1. Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer.
    Guo L; Song P; Xue X; Guo C; Han L; Fang Q; Ying J; Gao S; Li W
    J Immunother; 2019; 42(6):215-220. PubMed ID: 31145232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma.
    Song Z; Yu X; Zhang Y
    Lung Cancer; 2016 Sep; 99():166-71. PubMed ID: 27565935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer.
    Shin J; Chung JH; Kim SH; Lee KS; Suh KJ; Lee JY; Kim JW; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Bang SM; Lee JS
    Cancer Res Treat; 2019 Jul; 51(3):1086-1097. PubMed ID: 30428640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic changes in PD-L1 expression and CD8
    Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
    Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.
    Rojkó L; Reiniger L; Téglási V; Fábián K; Pipek O; Vágvölgyi A; Agócs L; Fillinger J; Kajdácsi Z; Tímár J; Döme B; Szállási Z; Moldvay J
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1219-1226. PubMed ID: 29675791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.
    Inamura K; Yokouchi Y; Kobayashi M; Ninomiya H; Sakakibara R; Nishio M; Okumura S; Ishikawa Y
    Cancer Med; 2017 Oct; 6(10):2347-2356. PubMed ID: 28925087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y
    Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.
    Sheng J; Fang W; Yu J; Chen N; Zhan J; Ma Y; Yang Y; Huang Y; Zhao H; Zhang L
    Sci Rep; 2016 Jan; 6():20090. PubMed ID: 26822379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy.
    Katsuya Y; Horinouchi H; Asao T; Kitahara S; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Watanabe S; Tsuta K; Ohe Y
    Lung Cancer; 2016 Sep; 99():4-10. PubMed ID: 27565906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
    Téglási V; Pipek O; Lózsa R; Berta K; Szüts D; Harkó T; Vadász P; Rojkó L; Döme B; Bagó AG; Tímár J; Moldvay J; Szállási Z; Reiniger L
    Clin Lung Cancer; 2019 Sep; 20(5):363-369.e2. PubMed ID: 31178388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer.
    Song P; Guo L; Li W; Zhang F; Ying J; Gao S
    J Immunother; 2019 Jan; 42(1):23-28. PubMed ID: 30407231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies.
    Nishii K; Hotta K; Ninomiya K; Kato Y; Ichihara E; Ohashi K; Ninomiya T; Kubo T; Rai K; Tabata M; Maeda Y; Kiura K
    Respir Investig; 2019 Sep; 57(5):460-465. PubMed ID: 31186170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
    Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
    Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
    Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
    Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
    Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM
    Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
    Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
    Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients.
    Fujimoto D; Uehara K; Sato Y; Sakanoue I; Ito M; Teraoka S; Nagata K; Nakagawa A; Kosaka Y; Otsuka K; Imai Y; Hamakawa H; Takahashi Y; Kokubo M; Tomii K
    Sci Rep; 2017 Sep; 7(1):11373. PubMed ID: 28900290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-blocks are suitable material for programmed cell death ligand-1 immunohistochemistry: Comparison of cell-blocks and matched surgical resection specimens in lung cancer.
    Pak MG; Roh MS
    Cytopathology; 2019 Nov; 30(6):578-585. PubMed ID: 31209979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
    Chen S; Wang RX; Liu Y; Yang WT; Shao ZM
    Int J Cancer; 2017 Mar; 140(6):1384-1395. PubMed ID: 27925176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
    Takada K; Kohashi K; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Seto T; Oda Y; Maehara Y
    Lung Cancer; 2019 Feb; 128():26-32. PubMed ID: 30642449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.